Clifford Swan Investment Counsel LLC grew its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 26.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 445,560 shares of the biopharmaceutical company’s stock after purchasing an additional 94,541 shares during the quarter. Bristol-Myers Squibb accounts for 1.5% of Clifford Swan Investment Counsel LLC’s portfolio, making the stock its 12th largest position. Clifford Swan Investment Counsel LLC’s holdings in Bristol-Myers Squibb were worth $27,304,000 at the end of the most recent quarter.
Other hedge funds have also recently modified their holdings of the company. Delphi Private Advisors LLC acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at $108,000. Massey Quick Simon & CO. LLC increased its position in shares of Bristol-Myers Squibb by 523.5% during the 3rd quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 1,492 shares during the period. Horan Capital Advisors LLC. acquired a new position in shares of Bristol-Myers Squibb during the 3rd quarter valued at $122,000. NuWave Investment Management LLC bought a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth $119,000. Finally, Atlantic Trust LLC bought a new stake in shares of Bristol-Myers Squibb during the 2nd quarter worth $111,000. Institutional investors own 71.49% of the company’s stock.
Shares of BMY stock opened at $62.06 on Friday. The company has a market capitalization of $107,913.73, a price-to-earnings ratio of 105.19, a PEG ratio of 1.72 and a beta of 0.98. The company has a quick ratio of 1.43, a current ratio of 1.55 and a debt-to-equity ratio of 0.59. Bristol-Myers Squibb Co has a 12-month low of $51.56 and a 12-month high of $70.05.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, May 1st. Stockholders of record on Friday, April 6th will be given a $0.40 dividend. The ex-dividend date of this dividend is Thursday, April 5th. This represents a $1.60 annualized dividend and a dividend yield of 2.58%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 271.19%.
Several equities research analysts have recently weighed in on the company. Jefferies Group set a $70.00 price objective on Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Friday. Argus reissued a “buy” rating and set a $66.43 price objective (down from $75.00) on shares of Bristol-Myers Squibb in a research note on Wednesday. ValuEngine lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Wednesday, March 7th. Bank of America raised their price objective on Bristol-Myers Squibb from $64.00 to $68.00 and gave the stock a “neutral” rating in a research note on Monday, March 5th. Finally, Vetr raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating and set a $60.72 price objective for the company in a research note on Thursday, February 1st. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $66.68.
ILLEGAL ACTIVITY WARNING: This story was first posted by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3295201/bristol-myers-squibb-co-bmy-shares-bought-by-clifford-swan-investment-counsel-llc.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.